Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 20Terminated 14Completed 12Recruiting 7Active not recruiting 7Not yet recruiting 5Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm, Residual 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Specimen Handling 32Magnetic Resonance Spectroscopy 21Biopsy 20Cyclophosphamide 16Nivolumab 10Paclitaxel 9Cisplatin 9Gemcitabine 8Bevacizumab 8venetoclax 7Vincristine 7Prednisone 7Doxorubicin 7Azacitidine 7pembrolizumab 6Radiotherapy 6Radiosurgery 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Taxes 5Rituximab 5Oxaliplatin 5Irinotecan 5Everolimus 5Capecitabine 5fludarabine phosphate 4fludarabine 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × ALT-803 × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡